These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 33886689)
1. Correction: Costs of continuing RTS,S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries. Baral R; Levin A; Odero C; Pecenka C; Tabu C; Mwendo E; Bonsu G; Bawa J; Dadzie JF; Charo J; Antwi-Agyei KO; Amponsa-Achianou K; Jalango RE; Mkisi R; Gordon S; Mzengeza T; Morgan W; Muhib F PLoS One; 2021; 16(4):e0250863. PubMed ID: 33886689 [TBL] [Abstract][Full Text] [Related]
2. The Costs of Implementing Vaccination With the RTS,S Malaria Vaccine in Five Sub-Saharan African Countries. Sicuri E; Yaya Bocoum F; Nonvignon J; Alonso S; Fakih B; Bonsu G; Kariuki S; Leeuwenkamp O; Munguambe K; Mrisho M; Were V; Sauboin C MDM Policy Pract; 2019; 4(2):2381468319896280. PubMed ID: 31903424 [No Abstract] [Full Text] [Related]
3. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786 [TBL] [Abstract][Full Text] [Related]
4. [The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination]. Vandoolaeghe P; Schuerman L Pan Afr Med J; 2018; 30():142. PubMed ID: 30374388 [TBL] [Abstract][Full Text] [Related]
5. Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials. Agnandji ST; Fernandes JF; Bache EB; Ramharter M Future Microbiol; 2015; 10(10):1553-78. PubMed ID: 26437872 [TBL] [Abstract][Full Text] [Related]
6. Decrease in circulating CD25(hi)Foxp3(+) regulatory T cells following vaccination with the candidate malaria vaccine RTS,S. Parsons E; Epstein J; Sedegah M; Villasante E; Stewart A Vaccine; 2016 Aug; 34(38):4618-4625. PubMed ID: 27443592 [TBL] [Abstract][Full Text] [Related]
7. The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination. Vandoolaeghe P; Schuerman L Expert Rev Vaccines; 2016 Dec; 15(12):1481-1493. PubMed ID: 27841689 [TBL] [Abstract][Full Text] [Related]
8. Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children. Ubillos I; Ayestaran A; Nhabomba AJ; Dosoo D; Vidal M; Jiménez A; Jairoce C; Sanz H; Aguilar R; Williams NA; Díez-Padrisa N; Mpina M; Sorgho H; Agnandji ST; Kariuki S; Mordmüller B; Daubenberger C; Asante KP; Owusu-Agyei S; Sacarlal J; Aide P; Aponte JJ; Dutta S; Gyan B; Campo JJ; Valim C; Moncunill G; Dobaño C BMC Med; 2018 Oct; 16(1):197. PubMed ID: 30376866 [TBL] [Abstract][Full Text] [Related]
9. Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa. Galactionova K; Tediosi F; Camponovo F; Smith TA; Gething PW; Penny MA Vaccine; 2017 Jan; 35(1):53-60. PubMed ID: 27890400 [TBL] [Abstract][Full Text] [Related]
10. RTS,S malaria vaccine pilot studies: addressing the human realities in large-scale clinical trials. van den Berg M; Ogutu B; Sewankambo NK; Biller-Andorno N; Tanner M Trials; 2019 May; 20(1):316. PubMed ID: 31151473 [TBL] [Abstract][Full Text] [Related]
11. Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure. Kurtovic L; Agius PA; Feng G; Drew DR; Ubillos I; Sacarlal J; Aponte JJ; Fowkes FJI; Dobaño C; Beeson JG BMC Med; 2019 Feb; 17(1):45. PubMed ID: 30798787 [TBL] [Abstract][Full Text] [Related]
12. The Advanced Development Pathway of the RTS,S/AS01 Vaccine. von Seidlein L Methods Mol Biol; 2019; 2013():177-187. PubMed ID: 31267502 [TBL] [Abstract][Full Text] [Related]
13. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. Tinto H; Otieno W; Gesase S; Sorgho H; Otieno L; Liheluka E; Valéa I; Sing'oei V; Malabeja A; Valia D; Wangwe A; Gvozdenovic E; Guerra Mendoza Y; Jongert E; Lievens M; Roman F; Schuerman L; Lusingu J Lancet Infect Dis; 2019 Aug; 19(8):821-832. PubMed ID: 31300331 [TBL] [Abstract][Full Text] [Related]
14. Safety and Immunogenicity of Seven Dosing Regimens of the Candidate RTS,S/AS01E Malaria Vaccine Integrated Within an Expanded Program on Immunization Regimen: A Phase II, Single-Center, Open, Controlled Trial in Infants in Malawi. Witte D; Cunliffe NA; Turner AM; Ngulube E; Ofori-Anyinam O; Vekemans J; Chimpeni P; Lievens M; Wilson TP; Njiram'madzi J; Mendoza YG; Leach A Pediatr Infect Dis J; 2018 May; 37(5):483-491. PubMed ID: 29432383 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519 [TBL] [Abstract][Full Text] [Related]
16. Differential Patterns of IgG Subclass Responses to Dobaño C; Santano R; Vidal M; Jiménez A; Jairoce C; Ubillos I; Dosoo D; Aguilar R; Williams NA; Díez-Padrisa N; Ayestaran A; Valim C; Asante KP; Owusu-Agyei S; Lanar D; Chauhan V; Chitnis C; Dutta S; Angov E; Gamain B; Coppel RL; Beeson JG; Reiling L; Gaur D; Cavanagh D; Gyan B; Nhabomba AJ; Campo JJ; Moncunill G Front Immunol; 2019; 10():439. PubMed ID: 30930896 [TBL] [Abstract][Full Text] [Related]
17. Mosquirix (RTS,S): a novel vaccine for the prevention of Plasmodium falciparum malaria. Wilby KJ; Lau TT; Gilchrist SE; Ensom MH Ann Pharmacother; 2012 Mar; 46(3):384-93. PubMed ID: 22408046 [TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. Abdulla S; Oberholzer R; Juma O; Kubhoja S; Machera F; Membi C; Omari S; Urassa A; Mshinda H; Jumanne A; Salim N; Shomari M; Aebi T; Schellenberg DM; Carter T; Villafana T; Demoitié MA; Dubois MC; Leach A; Lievens M; Vekemans J; Cohen J; Ballou WR; Tanner M N Engl J Med; 2008 Dec; 359(24):2533-44. PubMed ID: 19064623 [TBL] [Abstract][Full Text] [Related]
19. Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Sacarlal J; Aponte JJ; Aide P; Mandomando I; Bassat Q; Guinovart C; Leach A; Milman J; Macete E; Espasa M; Ofori-Anyinam O; Thonnard J; Corachan S; Dubois MC; Lievens M; Dubovsky F; Ballou WR; Cohen J; Alonso PL Vaccine; 2008 Jan; 26(2):174-84. PubMed ID: 18069097 [TBL] [Abstract][Full Text] [Related]
20. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Aponte JJ; Aide P; Renom M; Mandomando I; Bassat Q; Sacarlal J; Manaca MN; Lafuente S; Barbosa A; Leach A; Lievens M; Vekemans J; Sigauque B; Dubois MC; Demoitié MA; Sillman M; Savarese B; McNeil JG; Macete E; Ballou WR; Cohen J; Alonso PL Lancet; 2007 Nov; 370(9598):1543-51. PubMed ID: 17949807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]